Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRAS | P01112 | 14/20 | 0.53 |
| ▸ | ESR1 | P03372 | 13/20 | 0.53 |
| ▸ | ESR2 | Q92731 | 13/20 | 0.53 |
| ▸ | TOP1 | P11387 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.53 |
| ▸ | PKM | P14618 | 2/20 | 0.39 |
| ▸ | USP4 | Q13107 | 1/20 | 0.35 |
| ▸ | USP7 | Q93009 | 1/20 | 0.35 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.33 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14002816 | 0.86 | HRAS (0.61) | HRASESR1ESR2TOP1KDM4E | |
| SCHEMBL4857581 | 0.84 | HRAS (0.74) | HRASESR1ESR2TOP1KDM4E | |
| SCHEMBL9713948 | 0.83 | HRAS (0.73) | HRASESR1ESR2TOP1KDM4E | |
| SCHEMBL4858107 | 0.82 | PKM (0.39) | HRASESR1ESR2TOP1KDM4E | |
| SCHEMBL9714123 | 0.81 | HRAS (0.81) | HRASESR1ESR2TOP1KDM4E | |
| SCHEMBL7510361 | 0.81 | HRAS (0.76) | HRASESR1ESR2TOP1KDM4E | |
| Hydrochloric Acid SCHEMBL10688614 | 0.80 | KDM4E (0.76) | HRASESR1ESR2TOP1KDM4E | |
| Hydrochloric Acid SCHEMBL6548715 | 0.80 | KDM4E (0.76) | HRASESR1ESR2TOP1KDM4E | |
| Hydrochloric Acid SCHEMBL9124388 | 0.80 | KDM4E (0.76) | HRASESR1ESR2TOP1KDM4E | |
| SCHEMBL7500851 | 0.77 | HRAS (0.55) | HRASESR1ESR2TOP1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7449547-B2 | Process for the synthesis of distamycin and derivatives thereof using 1-methyl-4-formylamino-2-pyrrolecarbonyl chloride iteratively as an intermediate | NAXOPHARMA S.R.L. (IT) | 2008-11-11 | — | — | US | disclosed |
| US-20070060523-A1 | Process for the synthesis of distamycin and derivatives thereof using 1-methyl-4-formylamino-2-pyrrolecarbonyl chloride iteratively as an intermediate | NAXOSPHARMA S.R.L. (IT) | 2007-03-15 | — | — | US | disclosed |
| EP-1641753-B1 | PROCESS FOR THE SYNTHESIS OF DISTAMYCIN AND DERIVATIVES THEREOF USING 1-METHYL-4-FORMYLAMINO-2-PYRROLECARBONYL CHLORIDE ITERATIVELY AS AN INTERMEDIATE | NAXOSPHARMA S R L (IT) | 2006-10-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070060523-A1 | Process for the synthesis of distamycin and derivatives thereof using 1-methyl-4-formylamino-2-pyrrolecarbonyl chloride iteratively as an intermediate | DHPS, PCBP1, MRPL21 | HRAS 3606/4885ESR1 4748/4885ESR2 4665/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.